UNITED THERAPEUTICS Corp
For the period ended Jun 30, 2024. Filed Jul 31, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Jul 31, 2024
UTHR$588.61+1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| Three Months Ended June 30, 2024 | |||||||
|---|---|---|---|---|---|---|---|
| (Unaudited) | |||||||
| Common Stock · AdditionalPaid-inCapital · AccumulatedOtherComprehensiveLoss · TreasuryStock · Retained Earnings · Stockholders’ Equity | |||||||
| Shares · Amount | |||||||
| Balance, April 1, 2024 | 74.1 | $0.7 | $2,405.4 | $(15.6) | $(3,386.1) | $6,333.7 | $5,338.1 |
| Net income | — | — | — | — | — | 278.1 | 278.1 |
| Unrealized gain on available-for-sale debt securities | — | — | — | 1.8 | — | — | 1.8 |
| Defined benefit pension plan | — | — | — | (1.1) | — | — | (1.1) |
| Restricted stock units (RSUs) withheld for taxes | — | — | (0.1) | — | — | — | (0.1) |
| Share repurchase | — | — | 57.9 | — | (57.9) | — | — |
| Excise tax on net share repurchase | — | — | — | — | 0.5 | — | 0.5 |
| Exercise of stock options | 0.4 | — | 52.1 | — | — | — | 52.1 |
| Share-based compensation | — | — | 27.8 | — | — | — | 27.8 |
| Balance, June 30, 2024 | 74.5 | $0.7 | $2,543.1 | $(14.9) | $(3,443.5) | $6,611.8 | $5,697.2 |
| Three Months Ended June 30, 2023 | |||||||
|---|---|---|---|---|---|---|---|
| (Unaudited) | |||||||
| Common Stock · AdditionalPaid-inCapital · AccumulatedOtherComprehensiveLoss · TreasuryStock · Retained Earnings · Stockholders’ Equity | |||||||
| Shares · Amount | |||||||
| Balance, April 1, 2023 | 73.3 | $0.7 | $2,457.3 | $(38.8) | $(2,579.2) | $5,283.2 | $5,123.2 |
| Net income | — | — | — | — | — | 259.2 | 259.2 |
| Unrealized loss on available-for-sale debt securities | — | — | — | (11.0) | — | — | (11.0) |
| Defined benefit pension plan | — | — | — | (0.8) | — | — | (0.8) |
| Exercise of stock options | 0.2 | — | 24.7 | — | — | — | 24.7 |
| Share-based compensation | — | — | 15.7 | — | — | — | 15.7 |
| Balance, June 30, 2023 | 73.5 | $0.7 | $2,497.7 | $(50.6) | $(2,579.2) | $5,542.4 | $5,411.0 |
| Six Months Ended June 30, 2024 | |||||||
|---|---|---|---|---|---|---|---|
| (Unaudited) | |||||||
| Common Stock · AdditionalPaid-inCapital · AccumulatedOtherComprehensiveLoss · TreasuryStock · Retained Earnings · Stockholders’ Equity | |||||||
| Shares · Amount | |||||||
| Balance, January 1, 2024 | 73.7 | $0.7 | $2,549.0 | $(12.8) | $(2,579.2) | $6,027.1 | $5,984.8 |
| Net income | — | — | — | — | — | 584.7 | 584.7 |
| Foreign currency translation loss | — | — | — | 2.4 | — | — | 2.4 |
| Unrealized loss on available-for-sale debt securities | — | — | — | (1.7) | — | — | (1.7) |
| Defined benefit pension plan | — | — | — | (2.8) | — | — | (2.8) |
| Shares issued under employee stock purchase plan (ESPP) | — | — | 3.9 | — | — | — | 3.9 |
| RSUs withheld for taxes | — | — | (11.5) | — | — | — | (11.5) |
| Share repurchase | — | — | (142.1) | — | (857.9) | — | (1,000.0) |
| Excise tax on net share repurchase | — | — | — | — | (6.4) | — | (6.4) |
| Common stock issued for RSUs vested | 0.1 | — | — | — | — | — | — |
| Exercise of stock options | 0.7 | — | 94.3 | — | — | — | 94.3 |
| Share-based compensation | — | — | 49.5 | — | — | — | 49.5 |
| Balance, June 30, 2024 | 74.5 | $0.7 | $2,543.1 | $(14.9) | $(3,443.5) | $6,611.8 | $5,697.2 |
| 6 | United Therapeutics, a public benefit corporation |
| Six Months Ended June 30, 2023 | |||||||
|---|---|---|---|---|---|---|---|
| (Unaudited) | |||||||
| Common Stock · AdditionalPaid-inCapital · AccumulatedOtherComprehensiveLoss · TreasuryStock · Retained Earnings · Stockholders’ Equity | |||||||
| Shares · Amount | |||||||
| Balance, January 1, 2023 | 72.7 | $0.7 | $2,388.4 | $(55.5) | $(2,579.2) | $5,042.3 | $4,796.7 |
| Net income | — | — | — | — | — | 500.1 | 500.1 |
| Unrealized gain on available-for-sale debt securities | — | — | — | 8.9 | — | — | 8.9 |
| Defined benefit pension plan | — | — | — | (4.0) | — | — | (4.0) |
| Shares issued under ESPP | — | — | 3.4 | — | — | — | 3.4 |
| RSUs withheld for taxes | — | — | (13.5) | — | — | — | (13.5) |
| Common stock issued for RSUs vested | 0.1 | — | — | — | — | — | — |
| Exercise of stock options | 0.7 | — | 86.1 | — | — | — | 86.1 |
| Share-based compensation | — | — | 33.3 | — | — | — | 33.3 |
| Balance, June 30, 2023 | 73.5 | $0.7 | $2,497.7 | $(50.6) | $(2,579.2) | $5,542.4 | $5,411.0 |
| Quarterly Report | 7 |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.